Frequency, predictors, and outcomes of urine drug testing among patients with advanced cancer on chronic opioid therapy at an outpatient supportive care clinic. Issue 23 (10th August 2016)

• Record Type: Journal Article
• Authors: Arthur, Joseph A.; Edwards, Tonya; Lu, Zhanni; Reddy, Suresh; Hui, David; Wu, Jimin; Liu, Diane; Williams, Janet L.; Bruera, Eduardo
• Is Part Of: Cancer. Volume 122:Issue 23(2016)
• Page Start: 3732
• Page End: 3739
• Publication Date: 2016-08-10
• Subjects: aberrant -- abuse -- cancer -- diversion -- opioids -- palliative care -- urine drug test; Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.30240
• Languages: English
• ISSNs: 0008-543X

Abstract

Abstract : BACKGROUND: Data are limited on the use and outcomes of urine drug tests (UDTs) among patients with advanced cancer. The main objective of this study was to determine the factors associated with UDT ordering and results in outpatients with advanced cancer. METHODS: A retrospective chart review was conducted of 1058 patients who attended an outpatient supportive care clinic from March 2014 to November 2015. Sixty‐one patients who were receiving chronic opioid therapy and underwent UDTs were identified. A control group of 120 patients who did not undergo UDTs was selected for comparison. RESULTS: Sixty‐one of 1058 patients (6%) underwent UDTs, and 33 of 61 patients (54%) had abnormal results. Multivariate analysis indicated that the odds ratio for UDT ordering was 3.9 in patients who had positive Cut Down, Annoyed, Guilty, and Eye Opener (CAGE) questionnaire results ( P = .002), 4.41 in patients aged < 45 years ( P < .001), 5.58 in patients who had moderate‐to‐severe pain (Edmonton Symptom Assessment Scale pain scores ≥4; P < .001), 0.27 in patients with advanced‐stage cancer, ( P = .008), and 0.25 in patients who had moderate‐to‐severe fatigue ( P = .001). Among 52 abnormal UDT results in 33 patients, the most common opioid findings were prescribed opioids absent in urine (14 of 52 tests; 27%) and unprescribed opioids in urine (13 of 52 tests; 25%). CONCLUSIONS: UDTs were used infrequently among outpatients with advanced cancer who were receiving chronic opioid therapy. Younger age, positive CAGE questionnaire results, early stage cancer or no evidence of disease status, higher pain intensity, and lower fatigue scores were significant predictors of UDT ordering. More than 50% of UDT results were abnormal. More research is necessary to better characterize aberrant opioid use in patients with advanced cancer. Cancer 2016;122:3732‐9. © 2016 American Cancer Society . Abstract : Urine drug testing is used infrequently among patients with advanced cancer who are receiving outpatient chronic opioid therapy. The current results indicate that greater than 50% of the tests ordered produce abnormal results.